AZD 7325

Drug Profile

AZD 7325

Alternative Names: AZ-7325; AZD-7325

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca; University College London
  • Class Anxiolytics; Nootropics
  • Mechanism of Action GABA A alpha 2 receptor agonists; GABA A alpha 3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neurological disorders
  • Discontinued Anxiety disorders

Most Recent Events

  • 09 May 2017 Children's Hospital Medical Center plans a phase I trial for Fragile X syndrome in USA (NCT03140813)
  • 23 Jul 2015 Preclinical trials in Neurological disorders in United Kingdom (PO)
  • 23 Jul 2015 University College London plans a phase I trial for Neurological disorders in United Kingdom (UKCRN19179)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top